Risk factors for pneumothorax in advanced and/or metastatic soft tissue sarcoma patients during pazopanib treatment: a single-institute analysis.
BACKGROUND
After the approval of pazopanib for the treatment of soft tissue sarcoma (STS), pneumothorax was reported as an unexpected adverse event during pazopanib treatment. The incidence and risk factors of pneumothorax during pazopanib treatment for STSs have not been established yet.


METHODS
We retrospectively reviewed the cases of all of the STS patients treated with pazopanib between November 2012 and December 2014 at our institute and evaluated the prevalence, incidence, treatment details and risk factors for pneumothorax in the STS patients during pazopanib treatment.


RESULTS
A total of 58 patients were enrolled; 45 of them had lung and/or pleural lesions at the start of pazopanib treatment. During the median follow-up time of 219 days (range 23-659), 13 pneumothorax events occurred in six patients; the prevalence and incidence of pneumothorax were 10.3 % and 0.56 per treatment-year, respectively. The median onset of pneumothorax was day 115 (range 6-311). No patients died of pneumothorax, but pazopanib was interrupted in 10 events and chest drainage was performed in eight events. Pazopanib continuation or restart after the recovery from pneumothorax was conducted after 9 of the 13 events. The median progression-free survival of patients with and without pneumothorax events were 144 and 128 days (p = 0.89) and the median overall survival periods were 293 and 285 days (p = 0.69), respectively. By logistic regression analyses, the maximum diameter of the lung metastases ≥ 30 mm (OR 13.3, 95 % CI 1.1-155.4, p = 0.039) and a history of pneumothorax before the pazopanib induction (OR 16.6, 95 % CI 1.1-256.1, p = 0.045) were significantly predictive of pneumothorax.


CONCLUSIONS
In our retrospective analysis, pneumothorax was observed in 10.3 % of 58 STS patients during pazopanib treatment. The diameter of the lung metastases and a history of pneumothorax could be useful for evaluating the risk of pneumothorax in pazopanib treatment.
Department of Medical Oncology, Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Ariake, Tokyo, 135-8550, Japan.
Kenji
K
Nakano
Division of Pathology, Cancer Institute of the Japanese Foundation for Cancer Research, Tokyo, Japan.
Noriko
N
Motoi
Department of Medical Oncology, Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Ariake, Tokyo, 135-8550, Japan.
Junichi
J
Tomomatsu
Department of Orthopedic Surgery, Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan.
Tabu
T
Gokita
Department of Orthopedic Surgery, Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan.
Keisuke
K
Ae
Department of Orthopedic Surgery, Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan.
Taisuke
T
Tanizawa
Department of Orthopedic Surgery, Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan.
Seiichi
S
Matsumoto
Department of Medical Oncology, Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Ariake, Tokyo, 135-8550, Japan. s.takahashi-chemotherapy@jfcr.or.jp.
Shunji
S
Takahashi
Pazopanib; Pneumothorax; Soft tissue sarcoma; Tyrosine kinase inhibitor
Ann Oncol. 2014 Mar;25(3):719-24
24504442
Clin Sarcoma Res. 2014 Oct 01;4:14
25302110
Lancet. 2012 May 19;379(9829):1879-86
22595799
Ann Surg. 1999 May;229(5):602-10; discussion 610-2
10235518
J Clin Oncol. 2014 Oct 20;32(30):3374-82
25225436
J Thorac Oncol. 2008 Apr;3(4):351-7
18379352
N Engl J Med. 2005 Aug 18;353(7):701-11
16107623
J Pediatr Surg. 2015 Sep;50(9):1484-9
25783402
J Clin Oncol. 2009 Jan 20;27(3):404-10
19047292
Sarcoma. 2014;2014:145764
24683310
Eur J Cancer. 2015 Jul;51(10 ):1293-302
25899987
N Engl J Med. 2013 Aug 22;369(8):722-31
23964934
Clin Oncol (R Coll Radiol). 2014 Jun;26(6):357
24630810
Chest. 2010 Sep;138(3):510-8
20382720
Jpn J Clin Oncol. 1992 Jun;22(3):194-7
1518168
J Thorac Dis. 2011 Jun;3(2):138-40
22263077